Vaginal Carcinoma
~Introduction
Vaginal carcinoma is a rare malignant tumor arising from the epithelial lining of the vagina. It accounts for approximately 1–2% of all gynecological malignancies and is most commonly diagnosed in elderly women. Primary vaginal cancer must be differentiated from secondary involvement of the vagina by cancers of the cervix, vulva, endometrium, or ovary, which are far more common.
Despite its rarity, vaginal carcinoma is clinically significant due to delayed diagnosis, advanced stage at presentation, and proximity to vital pelvic organs such as the bladder and rectum. Early detection and appropriate management significantly improve prognosis.
~Epidemiology
Incidence: 0.5–1 per 100,000 women per year
Most commonly diagnosed in women above 60 years
Rare in women under 40 years
Squamous cell carcinoma is the most common histological type
Strong association with human papillomavirus (HPV) infection
~Etiology and Risk Factors
Several factors increase the risk of developing vaginal carcinoma:
1. Human Papillomavirus (HPV)
High-risk HPV types (16 and 18)
Associated with squamous cell carcinoma and vaginal intraepithelial neoplasia (VaIN)
2. Age
Increasing age is a major risk factor
Postmenopausal women are most affected
3. Previous Gynecological Malignancy
History of cervical cancer or hysterectomy for cervical neoplasia
4. Diethylstilbestrol (DES) Exposure
In utero exposure to DES
Associated with clear cell adenocarcinoma in young women
5. Smoking
Increases risk due to immunosuppression and HPV persistence
6. Immunosuppression
HIV infection
Organ transplant recipients
~Pathogenesis
Vaginal carcinoma develops from malignant transformation of vaginal epithelial cells. Persistent HPV infection leads to dysplasia and progression from vaginal intraepithelial neoplasia (VaIN) to invasive carcinoma. Chronic irritation, inflammation, and estrogen deficiency in postmenopausal women may contribute to malignant changes.
~Classification of Vaginal Carcinoma
1. Squamous Cell Carcinoma (SCC)
Accounts for 80–90% of cases
Arises from vaginal epithelium
Usually occurs in upper third of vagina
Associated with HPV infection
2. Adenocarcinoma
Clear cell adenocarcinoma linked to DES exposure
Occurs in younger women
Non-DES adenocarcinomas are rare
3. Melanoma
Very rare
Highly aggressive
Poor prognosis
4. Sarcoma
Includes embryonal rhabdomyosarcoma
Occurs in children (sarcoma botryoides)
5. Small Cell Carcinoma
Neuroendocrine origin
Extremely aggressive
~Clinical Features
Symptoms are often nonspecific, leading to delayed diagnosis.
Common Symptoms
Postmenopausal vaginal bleeding
Watery or foul-smelling vaginal discharge
Dyspareunia
Pelvic pain
Urinary symptoms (frequency, dysuria)
Rectal symptoms in advanced disease
Signs
Vaginal mass or ulcer
Friable, bleeding lesion
Induration of vaginal wall
~Diagnosis
1. Clinical Examination
Speculum examination reveals lesion
Bimanual and rectovaginal examination to assess spread
2. Biopsy
Essential for definitive diagnosis
Confirms histological type
3. Pap Smear
May detect VaIN or vaginal cancer
Not a primary screening tool
4. Imaging Studies
MRI pelvis: best for local staging
CT scan: detects lymph node involvement
PET-CT: identifies distant metastasis
5. Cystoscopy and Proctoscopy
To evaluate bladder and rectal involvement
~FIGO Staging of Vaginal Carcinoma
Stage I: Tumor confined to vaginal wall
Stage II: Tumor invades subvaginal tissue but not pelvic wall
Stage III: Tumor extends to pelvic wall
Stage IVA: Invasion of bladder or rectal mucosa
Stage IVB: Distant metastasis
~Management
Treatment depends on stage, location, histology, and patient factors.
Stage I
Radiotherapy (external beam + brachytherapy)
Surgery in selected cases (upper vaginal lesions)
Stage II
Combined external beam radiotherapy and brachytherapy
Chemoradiation may be used
Stage III and IV
Concurrent chemoradiation
Palliative radiotherapy for advanced disease
Surgical Management
Rarely used
Partial or total vaginectomy in early disease
Pelvic exenteration for recurrent disease
~Chemotherapy
Used as radiosensitizer
Cisplatin-based regimens
Limited role as primary treatment
~Prognosis
Prognosis depends on stage at diagnosis:
Stage I: 5-year survival ~80%
Stage II: 50–60%
Stage III: 30–40%
Stage IV: <20%
Early detection significantly improves survival.
~Complications
Local recurrence
Fistula formation
Radiation-induced cystitis or proctitis
Sexual dysfunction
Psychological distress
~Prevention
HPV vaccination
Smoking cessation
Regular gynecological follow-up
Surveillance in women with previous cervical cancer
Early treatment of VaIN
~Conclusion
Vaginal carcinoma is a rare but serious gynecological malignancy, predominantly affecting elderly women. Squamous cell carcinoma is the most common type and is strongly associated with HPV infection. Due to nonspecific symptoms, diagnosis is often delayed, leading to advanced-stage disease. Radiotherapy remains the mainstay of treatment, with surgery reserved for selected cases. Prevention through HPV vaccination and early detection of precursor lesions can significantly reduce disease burden. With timely diagnosis and appropriate treatment, favorable outcomes can be achieved in early-stage disease.
No comments:
Post a Comment